The “green list” will help protect patients from unreliable, illegally compounded GLP-1s and simplify screening for border security.
PSM led a coalition of organizations urging leaders of the Senate HELP and House Energy and Commerce committees to help strengthen the FDA’s ability to protect Americans from unsafe and counterfeit medicines and medical products.
A decade ago no one had heard of deadly counterfeit prescription pills. Victims’ families bravely spoke up, lobbied, and rallied for change.
Chinese companies that supplied U.S. compounders have turned to making generic semaglutide for markets where Novo Nordisk’s main patent is expiring in 2026.
Elle published an exposé about bad actors and loose regulation in the medical spa industry.
On August 7, the Partnership for Safe Medicines and ADAP Advocacy Association filed a complaint asking the New York State Board of Pharmacy to take regulatory action against a pharmacy that allegedly sold counterfeit HIV medicine to a Queens, New York patient.
PSM and ADAP Advocacy Association filed an official complaint with the State of New York regarding allegations that City Plus Care Pharmacy Inc. dispensed counterfeit HIV medication to a patient in Queens, New York.
Statistics in the agency’s Report on the State of Pharmaceutical Quality show that active pharmaceutical ingredient (API) sites that solely supply compounding pharmacies are disproportionately high risk.
The proposed updates aim to help address safety concerns created by pharmacies reselling compounded sterile drugs purchased from outsourcing facilities.
The Pennsylvania Attorney General filed charges against a pharmacy owner and the Ohio Board of Pharmacy revoked licenses to protect patients.